Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on Top Healthcare Stocks: Legend Biotech (LEGN), Tonix Pharma (TNXP)

Tipranks - Tipranks - Tue Apr 21, 7:22AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Legend Biotech (LEGN), Tonix Pharma (TNXP) and Immunocore Holdings (IMCR) with bullish sentiments.

Claim 30% Off TipRanks

Legend Biotech (LEGN)

In a report released today, Kostas Biliouris from Oppenheimer reiterated a Buy rating on Legend Biotech, with a price target of $75.00. The company’s shares closed last Friday at $21.17.

According to TipRanks.com, Biliouris is a 2-star analyst with an average return of 1.0% and a 42.9% success rate. Biliouris covers the Healthcare sector, focusing on stocks such as Entrada Therapeutics Inc, Sarepta Therapeutics, and Prime Medicine, Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Legend Biotech with a $53.73 average price target, representing a 153.3% upside. In a report issued on April 7, RBC Capital also maintained a Buy rating on the stock with a $62.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Tonix Pharma (TNXP)

In a report released today, James Molloy from Alliance Global Partners reiterated a Buy rating on Tonix Pharma, with a price target of $65.00. The company’s shares closed last Friday at $13.98, close to its 52-week low of $6.76.

According to TipRanks.com, Molloy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -21.7% and a 25.9% success rate. Molloy covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Neurosense Therapeutics Ltd., and Intensity Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tonix Pharma with a $51.00 average price target.

Immunocore Holdings (IMCR)

Oppenheimer analyst Jeff Jones maintained a Buy rating on Immunocore Holdings today and set a price target of $86.00. The company’s shares closed last Friday at $31.45, close to its 52-week low of $27.19.

According to TipRanks.com, Jones is a 5-star analyst with an average return of 22.7% and a 46.2% success rate. Jones covers the Healthcare sector, focusing on stocks such as ArriVent BioPharma, Inc., Perspective Therapeutics, and Corvus Pharmaceuticals. ;'>

Currently, the analyst consensus on Immunocore Holdings is a Moderate Buy with an average price target of $62.67, implying a 96.8% upside from current levels. In a report issued on April 14, Wells Fargo also maintained a Buy rating on the stock with a $60.00 price target.

Read More on LEGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).